Frank R. Lichtenberg
- Published in print:
- 2009
- Published Online:
- February 2010
- ISBN:
- 9780199550685
- eISBN:
- 9780191720543
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780199550685.003.0015
- Subject:
- Public Health and Epidemiology, Public Health
This chapter tests the hypothesis that medical innovation has reduced the age-adjusted nursing home residence rate, and estimates the contribution of medical innovation to the decline in the rate of ...
More
This chapter tests the hypothesis that medical innovation has reduced the age-adjusted nursing home residence rate, and estimates the contribution of medical innovation to the decline in the rate of nursing home residence during the period 1985–1999. It investigates the effects of four types of medical innovation: drug innovation, and innovation in three types of procedures (therapeutic and preventive, diagnostic, and laboratory procedures).Less
This chapter tests the hypothesis that medical innovation has reduced the age-adjusted nursing home residence rate, and estimates the contribution of medical innovation to the decline in the rate of nursing home residence during the period 1985–1999. It investigates the effects of four types of medical innovation: drug innovation, and innovation in three types of procedures (therapeutic and preventive, diagnostic, and laboratory procedures).
Neumann Peter J., Cohen Joshua T., and Ollendorf Daniel A
- Published in print:
- 2021
- Published Online:
- May 2021
- ISBN:
- 9780197512883
- eISBN:
- 9780197512913
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/oso/9780197512883.003.0010
- Subject:
- Public Health and Epidemiology, Epidemiology, Public Health
Value-based pricing aims to optimize incentives for pharmaceutical companies making drug development investment decisions. To promote alignment of prices and value, this chapter recommends that ...
More
Value-based pricing aims to optimize incentives for pharmaceutical companies making drug development investment decisions. To promote alignment of prices and value, this chapter recommends that Medicare, Medicaid, and commercial insurers build value assessment into their coverage decisions. Before doing so, it explores alternatives that purport to make this alignment unnecessary. The first, cost-recovery pricing, reimburses drug companies for only their costs, rather than for value. While cost-recovery prices can be low, they reward high internal costs rather than better drugs. Prizes and subscription plans pay a lump sum, rather than paying for each treated patient, but they still require value assessment to set the size of the prize or subscription fee. Radical alternatives suggest having the government develop new drugs. Whether the government would be effective remains unknown. Nonetheless, it would, like private companies, have to prioritize investments, requiring something like value assessment to do so.Less
Value-based pricing aims to optimize incentives for pharmaceutical companies making drug development investment decisions. To promote alignment of prices and value, this chapter recommends that Medicare, Medicaid, and commercial insurers build value assessment into their coverage decisions. Before doing so, it explores alternatives that purport to make this alignment unnecessary. The first, cost-recovery pricing, reimburses drug companies for only their costs, rather than for value. While cost-recovery prices can be low, they reward high internal costs rather than better drugs. Prizes and subscription plans pay a lump sum, rather than paying for each treated patient, but they still require value assessment to set the size of the prize or subscription fee. Radical alternatives suggest having the government develop new drugs. Whether the government would be effective remains unknown. Nonetheless, it would, like private companies, have to prioritize investments, requiring something like value assessment to do so.
Brent Stockwell
- Published in print:
- 2013
- Published Online:
- November 2015
- ISBN:
- 9780231152136
- eISBN:
- 9780231525527
- Item type:
- book
- Publisher:
- Columbia University Press
- DOI:
- 10.7312/columbia/9780231152136.001.0001
- Subject:
- Public Health and Epidemiology, Public Health
After more than fifty years of blockbuster drug development, skeptics are beginning to fear we are reaching the end of drug discovery to combat major diseases. This book describes this dilemma and ...
More
After more than fifty years of blockbuster drug development, skeptics are beginning to fear we are reaching the end of drug discovery to combat major diseases. This book describes this dilemma and the powerful techniques that may bring drug research into the twenty-first century. Filled with absorbing stories of breakthroughs, this book begins with the scientific achievements of the twentieth century that led to today’s drug innovations. We learn how the invention of mustard gas in World War I led to early anti-cancer agents and how the efforts to decode the human genome might lead to new approaches in drug design. The book then turns to the seemingly incurable diseases we face today, such as Alzheimer’s, many cancers, and others with no truly effective medicines, and details the cellular and molecular barriers thwarting scientists equipped with only the tools of traditional pharmaceutical research. Scientists are now developing methods to combat these complexities—technologies for constructing and testing millions of drug candidates, sophisticated computational modeling, and entirely new classes of drug molecules—all with an eye toward solving the most profound mysteries of living systems and finding cures for intractable diseases. If successful, these methods will unlock a vast terrain of untapped drug targets that could lead to a bounty of breakthrough medicines.Less
After more than fifty years of blockbuster drug development, skeptics are beginning to fear we are reaching the end of drug discovery to combat major diseases. This book describes this dilemma and the powerful techniques that may bring drug research into the twenty-first century. Filled with absorbing stories of breakthroughs, this book begins with the scientific achievements of the twentieth century that led to today’s drug innovations. We learn how the invention of mustard gas in World War I led to early anti-cancer agents and how the efforts to decode the human genome might lead to new approaches in drug design. The book then turns to the seemingly incurable diseases we face today, such as Alzheimer’s, many cancers, and others with no truly effective medicines, and details the cellular and molecular barriers thwarting scientists equipped with only the tools of traditional pharmaceutical research. Scientists are now developing methods to combat these complexities—technologies for constructing and testing millions of drug candidates, sophisticated computational modeling, and entirely new classes of drug molecules—all with an eye toward solving the most profound mysteries of living systems and finding cures for intractable diseases. If successful, these methods will unlock a vast terrain of untapped drug targets that could lead to a bounty of breakthrough medicines.
